RESEARCH ARTICLE
AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection Stefan Garczyk1, Saskia von Stillfried1, Wiebke Antonopoulos1, Arndt Hartmann2 Michael G. Schrauder3, Peter A. Fasching3, Tobias Anzeneder4, Andrea Tannapfel5, Yavuz Ergönenc6, Ruth Knüchel1, Michael Rose1☯‡, Edgar Dahl1☯‡* 1 Molecular Oncology Group, Institute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany, 2 Institute of Pathology, University Hospital Erlangen, Erlangen, Germany, 3 Department of Gynaecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany, 4 Patients' Tumor Bank of Hope (PATH) Foundation, München, Germany, 5 Institute of Pathology, Ruhr-University Bochum, Bochum, Germany, on behalf of the PATH Biobank group, 6 Department for Senology, St Anna Hospital, Herne, Germany, on behalf of the PATH Biobank group ☯ These authors contributed equally to this work. ‡ MR and ED are co-senior authors on this work. * [email protected] OPEN ACCESS Citation: Garczyk S, von Stillfried S, Antonopoulos W, Hartmann A, Schrauder MG, Fasching PA, et al. (2015) AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection. PLoS ONE 10(4): e0122106. doi:10.1371/journal.pone.0122106 Academic Editor: Xin-Yuan Guan, The University of Hong Kong, CHINA Received: December 18, 2014 Accepted: February 20, 2015 Published: April 15, 2015 Copyright: © 2015 Garczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: The data used in this study are owned by The Cancer Genome Atlas Network. The specific sample IDs used can be found in S5 Table, and the AGR3 expression data as well as the corresponding clinical data can be downloaded using the following URLs: http://www.cbioportal.org/ (cancer study name: Breast Invasive Carcinoma (TCGA, Provisional); IlluminaHiSeq expression data for AGR3) https://tcga-data.nci.nih.gov/tcga/ tcgaDownload.jsp (corresponding clinical data).
Abstract Blood-based early detection of breast cancer has recently gained novel momentum, as liquid biopsy diagnostics is a fast emerging field. In this study, we aimed to identify secreted proteins which are up-regulated both in tumour tissue and serum samples of breast cancer patients compared to normal tissue and sera. Based on two independent tissue cohorts (n = 75 and n = 229) and one serum cohort (n = 80) of human breast cancer and healthy serum samples, we characterised AGR3 as a novel potential biomarker both for breast cancer prognosis and early breast cancer detection from blood. AGR3 expression in breast tumours is significantly associated with oestrogen receptor α (P
AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection Stefan Garczyk1, Saskia von Stillfried1, Wiebke Antonopoulos1, Arndt Hartmann2 Michael G. Schrauder3, Peter A. Fasching3, Tobias Anzeneder4, Andrea Tannapfel5, Yavuz Ergönenc6, Ruth Knüchel1, Michael Rose1☯‡, Edgar Dahl1☯‡* 1 Molecular Oncology Group, Institute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany, 2 Institute of Pathology, University Hospital Erlangen, Erlangen, Germany, 3 Department of Gynaecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany, 4 Patients' Tumor Bank of Hope (PATH) Foundation, München, Germany, 5 Institute of Pathology, Ruhr-University Bochum, Bochum, Germany, on behalf of the PATH Biobank group, 6 Department for Senology, St Anna Hospital, Herne, Germany, on behalf of the PATH Biobank group ☯ These authors contributed equally to this work. ‡ MR and ED are co-senior authors on this work. * [email protected] OPEN ACCESS Citation: Garczyk S, von Stillfried S, Antonopoulos W, Hartmann A, Schrauder MG, Fasching PA, et al. (2015) AGR3 in Breast Cancer: Prognostic Impact and Suitable Serum-Based Biomarker for Early Cancer Detection. PLoS ONE 10(4): e0122106. doi:10.1371/journal.pone.0122106 Academic Editor: Xin-Yuan Guan, The University of Hong Kong, CHINA Received: December 18, 2014 Accepted: February 20, 2015 Published: April 15, 2015 Copyright: © 2015 Garczyk et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: The data used in this study are owned by The Cancer Genome Atlas Network. The specific sample IDs used can be found in S5 Table, and the AGR3 expression data as well as the corresponding clinical data can be downloaded using the following URLs: http://www.cbioportal.org/ (cancer study name: Breast Invasive Carcinoma (TCGA, Provisional); IlluminaHiSeq expression data for AGR3) https://tcga-data.nci.nih.gov/tcga/ tcgaDownload.jsp (corresponding clinical data).
Abstract Blood-based early detection of breast cancer has recently gained novel momentum, as liquid biopsy diagnostics is a fast emerging field. In this study, we aimed to identify secreted proteins which are up-regulated both in tumour tissue and serum samples of breast cancer patients compared to normal tissue and sera. Based on two independent tissue cohorts (n = 75 and n = 229) and one serum cohort (n = 80) of human breast cancer and healthy serum samples, we characterised AGR3 as a novel potential biomarker both for breast cancer prognosis and early breast cancer detection from blood. AGR3 expression in breast tumours is significantly associated with oestrogen receptor α (P
